Read More

Sight Sciences To Feature Interactive Panel Discussions Of Real-World Use Of The OMNI Surgical System As A Standalone Glaucoma Treatment At American Academy Of Ophthalmology Annual Meeting October 1-2

MENLO PARK, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), today announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a

SGHT

Read More

CinCor Pharma Announces Late-Breaking Presentation Of Phase 2 BrigHtn Data For Baxdrostat In Treatment-Resistant Hypertension At The Upcoming 2022 American Heart Association Scientific Sessions : November 7

WALTHAM, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with

CINC

Read More

TCR2 Therapeutics Announces Topline Results From Phase 1 Portion Of gavo-cel Phase 1/2 Trial; Showed ‘Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%’

- Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit - Second RECIST partial response in ovarian cancer supports

TCRR